6
Carla van Tienen Medical Research Counci [email protected] urvival with HIV-1, HIV-2 and HTLV-1 in Guinea-Biss

Carla van Tienen Medical Research Council carlavantienen@gmail

  • Upload
    zonta

  • View
    26

  • Download
    0

Embed Size (px)

DESCRIPTION

Carla van Tienen Medical Research Council [email protected]. Survival with HIV-1, HIV-2 and HTLV-1 in Guinea-Bissau. Community cohort study : Adult residents ( ≥ 15 years) of the Cai ó village Cross-sectional surveys in 1990, 1997 and 2007 - PowerPoint PPT Presentation

Citation preview

Page 1: Carla van Tienen Medical Research Council carlavantienen@gmail

Carla van Tienen

Medical Research Council

[email protected]

Survival with HIV-1, HIV-2 and HTLV-1 in Guinea-Bissau

Page 2: Carla van Tienen Medical Research Council carlavantienen@gmail

• Community cohort study:– Adult residents (≥ 15 years) of the Caió village – Cross-sectional surveys in 1990, 1997 and 2007– 4 in detail observational studies in 1991, 1996, 2003

and 2006– Rolling census recording survival status

• Analysis:– Kaplan-Meier– Cox regression

Methods

Page 3: Carla van Tienen Medical Research Council carlavantienen@gmail

Results: follow-up

Total 5376

Deaths 1089 (20%)

Median follow-up time 10.9 years (4 d – 20 y)

Lost to follow-up 177 (3%)

Started on ART 24 (0.4%)

Seroconversions 209 (4%)

Page 4: Carla van Tienen Medical Research Council carlavantienen@gmail

At risk (events):

HIV negative 4797 (232) 3252 (253) 2785 (189) 1438 (104) 205

HIV-1 117 (25) 36 (16) 12 (2) 1 (0) 0

HIV-2 285 (42) 204 (35) 145 (24) 60 (9) 9

HIV-1/2 dual 53 (17) 25 (4) 11 (3) 0 (0) 0

0.0

00

.25

0.5

00

.75

1.0

0

su

rviv

al prob

ab

ility

0 5 10 15 19analysis time

uninfected

HIV-2

HIV-1/2 dual

HIV-1

uninfected

Unadjusted survival HIV-1 and HIV-2S

urv

iva

l pro

bab

ility

(%

)

Time since diagnosis (years)

Page 5: Carla van Tienen Medical Research Council carlavantienen@gmail

At risk (events):

HIV/HTLV-1 neg 4797 (232) 3252 (253) 2785 (189) 1438 (104) 205

HIV-2 285 (42) 204 (35) 145 (24) 60 (9) 9

HTLV-1 229 (30) 141 (25) 107 (13) 48 (3) 9

HTLV-1/HIV-2 69 (13) 45 (14) 26 (4) 12 (2) 3

0.0

00

.25

0.5

00

.75

1.0

0su

rviv

al pro

bab

ility

0 5 10 15 19analysis time

uninfected

uninfected

HTLV-1 HIV-2

HTLV-1/HIV-2

Unadjusted survival HTLV-1 and HIV-2S

urv

iva

l pro

bab

ility

(%

)

Time since diagnosis (years)

Page 6: Carla van Tienen Medical Research Council carlavantienen@gmail

Thank you !